Verastem (VSTM) EBITDA (2011 - 2026)
Verastem (VSTM) posted quarterly EBITDA of -$44.9 million for Q1 2026, down 1.64% year-over-year from -$45.6 million in Q1 2025, and down 8.25% quarter-over-quarter from -$41.5 million in Q4 2025.
Powered by 
Analysis
Verastem (VSTM) EBITDA (2011 - 2026) Analysis & Trends
Verastem's EBITDA history runs 16 years deep, the most recent figure standing at -$44.9 million for Q1 2026.
- In Q1 2026, EBITDA fell 1.64% year-over-year to -$44.9 million; the TTM figure through Mar 2026 stood at -$170.9 million (down 30.35% YoY), while the FY2025 annual figure was -$170.1 million, down 47.99% from the prior year.
- EBITDA for Q1 2026 stood at -$44.9 million, down from -$41.5 million in the prior quarter.
- The five-year high for EBITDA was -$16.8 million in Q4 2022, with the low at -$44.9 million in Q1 2026.
- The 5-year median for EBITDA is -$28.1 million (2024), against an average of -$29.1 million.
- The sharpest annual moves came in 2024 and 2025: EBITDA advanced 9.93% in 2024, then slumped 139.45% in 2025.
- Verastem's EBITDA stood at -$16.8 million in 2022, then slumped by 84.85% to -$31.1 million in 2023, then retreated by 1.45% to -$31.6 million in 2024, then plunged by 31.29% to -$41.5 million in 2025, then fell by 8.25% to -$44.9 million in 2026.
- Business Quant data shows VSTM's EBITDA at -$44.9 million in Q1 2026, -$41.5 million in Q4 2025, and -$40.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Verastem | 788.41 Mn | 652.06 Mn | 36.32 Mn | -32.71 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.71 Mn |
| Mar 31, 2026 | -44.90 Mn |
| Dec 31, 2025 | -41.46 Mn |
| Sep 30, 2025 | -40.71 Mn |
| Jun 30, 2025 | -43.76 Mn |
| Mar 31, 2025 | -44.16 Mn |
| Dec 31, 2024 | -31.58 Mn |
| Sep 30, 2024 | -37.02 Mn |
| Jun 30, 2024 | -18.27 Mn |
| Mar 31, 2024 | -28.05 Mn |
| Dec 31, 2023 | -31.14 Mn |
| Sep 30, 2023 | -21.31 Mn |
| Jun 30, 2023 | -20.29 Mn |
| Mar 31, 2023 | -19.34 Mn |
| Dec 31, 2022 | -16.85 Mn |
| Sep 30, 2022 | -17.71 Mn |
| Jun 30, 2022 | -21.40 Mn |
| Mar 31, 2022 | -16.98 Mn |
| Dec 31, 2021 | -16.51 Mn |
| Sep 30, 2021 | -14.85 Mn |